ABSTRACT Dose-response relationships of the cholinergic antagonist, atropine methonitrate, and the beta-adrenergic agonist, salbutamol, were examined by cumulative dose techniques. A wet aerosol, 15 mg atropine methonitrate produced a maximum response. The response to 200 ,ug of salbutamol from a pressurised aerosol was close to maximum. Secondly, the bronchodilator response of salbutamol 200 ,ug was compared with atropine methonitrate 2 mg and placebo in 18 asthmatic patients in a randomised crossover study. In 11 of them the bronchodilator response of the combination of salbutamol and atropine methonitrate was evaluated. Atropine methonitrate produced a similar peak bronchodilator effect to salbutamol, but its effect was more prolonged, the response being significantly greater at four and six hours than with salbutamol. The combination of drugs produced a significantly greater and more lasting bronchodilatation than either of the drugs alone. Despite mild side effects, atropine methonitrate, either alone or in combination with an adrenergic drug, appears to have a place in the treatment of severe reversible airway obstruction not adequately controlled by conventional treatment.
Substances containing atropine have been used for many decades in the treatment of asthma and several aerosol preparations combining isoprenaline with atropine have been used to give a more lasting effect than isoprenaline alone. These have attracted less attention, however, than the newer beta-adrenergic agonists, such as salbutamol, which similarly provide an increased duration of effect. This study attempts to assess the relative potency of atropine methonitrate, a quaternary ammonium salt of atropine that has a bronchodilator effect in bronchial asthma (Chamberlain et al, 1962; Kennedy and Thursby-Pelham, 1964) and in chronic bronchitis (Altounyan, 1964) . It has been compared with a standard therapeutic dose of salbutamol, and the bronchodilator effect obtained by combining atropine methonitrate and salbutamol has been assessed.
Methods
All patients gave informed consent before the studies. In both dose response and comparative trials xanthines were withheld for 48 hours and 'Present address: Brompton Hospital, Fulham Road, London SW3. adrenergic agonists for at least nine hours before the studies, which started at about 0900. Dose responses for salbutamol and atropine methonitrate were studied in 12 male patients with bronchial asthma. Their clinical characteristics are shown in table 1. Eight patients were studied for each drug, four patients were common to both groups. Measurements were made of the FEV, the best of three readings being taken. In testing salbutamol the technique of Shenfield and Patterson (1973) was used. The patient inhaled one puff from a metered dose inhaler estimated to deliver 100 ,ug per puff. After this, at five-minute intervals, measurements of the FEV1 were repeated until there was no further increase. A second puff of salbutamol was then inhaled and measurements taken as before. This was followed by two puffs and the procedure was repeated until the FEV, remained unchanged and a final two puffs were administered. In this way the cumulative dose administered was one, two, four, and six puffs. The average duration of the test was 90 minutes (range 70-100).
The peak response to atropine methonitrate is not reached until after about 40 minutes but is 45 FEV1 of the two drugs were similar but that of atropine methonitrate was more prolonged and at four and six hours was significantly greater than with salbutamol. Atropine methonitrate caused a greater fall in lung volumes than salbutamol at two hours, but these differences were not statistically significant.
The results for the combination of atropine 4 6 methonitrate with salbutamol are shown for FEV1 and sGaw in table 3. In this group of 11 patients for salbutamol the combination produced a considerably greater and longer lasting effect on FEV1 than either drug alone, and this difference was significant at ropine metho-two, four, and six hours. This combination prorate produced duced a significantly greater rise in sGaw than eline of 36%. either drug alone, and the fall in total lung 10% with the capacity (TLC), FRC, and RV were significantly At statistically greater than with salbutamol alone. rise after the Only small changes in pulse rate were observed tum broncho-after administration of any of the drugs. (Altounyan, 1964) . Although patients with chronic bronchitis may respond well to atropine (Crompton, 1968) , the presence of chronic bronchitis in 14 of our 18 asthmatics was probably not related to the relative efficacy of atropine. In asthmatics the presence or absence of chronic bronchitis had no influence on the relative efficacy of the cholinergic antagonist, ipratropium bromide, compared with terbutaline (Ruffin et al, 1977) . The dose of atropine methonitrate used in previous studies was varied considerably. Altounyan (1964) reported that 0-05 mg of atropine methonitrate as a wet aerosol produced maximum bronchodilatation. Kiviloog (1973) , on the other hand, used a dose of 2 mg as a wet aerosol. The doEeresponse curve shows that a maximum peak response was achieved with a dose of 1-5 mg. A dose of 005 mg, as advocated by Altounyan, is unlikely to produce a maximal response, whereas the dose of 2 mg used in our drug comparison trial should have ensured this. The observation (Cavanaugh and Cooper, 1976 ) that a larger dose (005 to 0-1 mg/kilo) of atropine sulphate is required to produce maximum response, may be explained by the lesser potency of atropine sulphate compared with atropine methonitrate (Malpass, 1951; Altounyan, 1964; Goodman and Gilman, 1970) .
It was of particular interest that although apparently adequate doses were administered, bronchodilatation was appreciably greater when both drugs were administered together. The response to the combination was about equal to the sum of the responses to the drugs individually. We also tested three patients with terbutaline, another adrenergic drug, and the same increased bronchodilator effect as with salbutamol was found when the combination of terbutaline and atropine methonitrate was compared with either drug alone. Chamberlain et al (1962) and Kennedy and Thursby-Pelham (1964) previously reported a more prolonged bronchodilator effect from the combination of atropine methylnitrate with isoprenaline. Cavanaugh and Cooper (1976) failed to show any potentiation of bronchodilatation when isoprenaline was administered together with atropine sulphate, 01 mg/kilo, to asthmatic children. They suggest that the previous results may have been due to the use of suboptimal doses of atropine. In the present investigation, however, each drug was administered in doses that produced close to maximum bronchodilatation for the drug concerned, so the increased bronchodilatation produced by the combination of the two drugs is unlikely to be due to suboptimal dosage.
The additional bronchodilatation achieved by the combination of the two drugs may be related to differences in their pharmacological action (Offermeier and van den Brink, 1974) or to differences in receptor sites within the airways (Ingram et al, 1977) . Because of these differences in action, the effects of the two drugs can be additive. This has been shown in the isolated trachea of animals (Offermeier and van den Brink, 1974) . When combined with an adrenergic agonist, neither atropine sulphate (Cavanaugh and Cooper, 1976) nor ipratropium bromide have produced significantly greater bronchodilatation than either drug alone (Petrie and Palmer, 1975; Ruffin et al, 1977) . So far, greater bronchodilatation by the combination of an anticholinergic drug and an adrenergic agonist has been produced in patients only when atropine methonitrate has been used. Evidently this compound is more potent in this regard than other atropine derivatives. We found that for patients with troublesome chronic asthma, the additive bronchodilator response of an optimal dose of atropine methonitrate combined with salbutamol was substantial, as shown by a mean increase of the FEV1 of 0 7 1.
A disadvantage with atropine methonitrate is that it may produce side effects. Our patients had no significant rise in heart rate or facial flushing after atropine methonitrate. With longer term administration, dryness of the mouth and mild visual blurring for close objects has occurred. In our experience such symptoms have not been severe enough to require cessation of treatment. The patients considered that the benefit of the treatment considerably outweighed the incoiivenience of the mild side effects.
Although a pressurised aerosol would be more convenient, when this is not available, atropine methonitrate can be administered as a wet aerosol from a hand nebuliser. 
